New hope for breast cancer patients with low platelets from T-DM1
NCT ID NCT07257809
First seen Jan 05, 2026 · Last updated Jun 23, 2026 · Updated 22 times
Summary
This study tests whether the drug Hetrombopag can safely raise platelet counts in breast cancer patients who developed low platelets (thrombocytopenia) after T-DM1 treatment. About 56 participants will take Hetrombopag tablets daily for two weeks per cycle. The goal is to see if this helps maintain platelet levels so patients can continue their cancer therapy without delays.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen Memorial Hospital
RECRUITINGGuangzhou, Guangdong, 510120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hetrombopag Olamine Tablets
What this could lead to
If it works, this could help breast cancer patients avoid delays or dose reductions in their T-DM1 therapy by preventing low platelet counts.
What could go wrong
This is a small, early-phase study with only 56 participants and no comparison group, so results may not apply broadly. The drug may not effectively raise platelets or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.